Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A 

With $20.4m in Series A funding from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market

Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn: “The clinical validation results of Ataraxis Breast–the first AI-native prognostic/predictive test for breast cancer patients are impressive.”

NEW YORK – Ataraxis AI is developing artificial intelligence-driven digital pathology tests that it believes may provide faster, more accurate, and more cost-effective answers to clinical questions about cancer patients' outcomes and recurrences than traditional molecular tests on the market.

Startup Ataraxis, which emerged from stealth Thursday, has developed a model that can predict the risk severity of breast cancer up to 30% more accurately than current tests.

In this NeurIPS 2024 Workshop paper, we demonstrate the importance of hyperparameter tuning in training digital pathology AI foundation models.

We describe the development and validation of Ataraxis Breast, the first AI-native breast cancer prognostication tool.